CoChat
Cited by 45

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma

Becker, K, Marchenko, N D, Maurice, M, Moll, U M · 2007 · Cell Death & Differentiation

Abstract

Neuroblastoma (NB) is the most common solid malignancy in childhood and its prognosis is still generally poor. In contrast to many other cancers, mutations of the p53 tumor suppressor are rare. Instead, significant cytosolic sequestration of wtp53 is one of several mechanisms that attenuate p53 function in this cancer. Here, we report that aberrant p53 hyperubiquitylation contributes to p53 cytoplasmic sequestration in NB. NB lines constitutively harbor an elevated portion of wtp53 as stable ubiquitylated species confined to the cytoplasm. p53 hyperubiquitylation is not due to dysregulation by Hdm2 or proteasomal dysfunction. Instead, the defect lies in p53 regulation by HAUSP, a major p53-deubiquitylating enzyme. In contrast to non-NB cancer cells with nuclear p53 and normal ubiquitylation, p53 from NB cells shows impaired HAUSP interaction. Conversely, interference with p53 hyperubiquitylation in NB cells by Nutlin 3a or by a C-terminal p53 peptide (aa 305-393) results in p53 relocalization from the cytoplasm to the nucleus, and in case of Nutlin, in reactivation of p53's transcriptional and apoptotic functions. Moreover, nutlin and camptothecin act synergistically in inducing NB cell apoptosis. Hence, this study strengthens the rationale for targeting p53 deubiquitylation by drugs like Nutlin as a promising new strategy in NB therapy.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.cdd.4402126

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 31

  1. Tweddle DA, Pinkerton CR, Lewis IJ, Ellershaw C, Cole M, Pearson AD . OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol 2001; 36: 239–242. · doi:10.1002/1096-911x(20010101)36:1<239::aid-mpo1058>3.0.co;2-g
  2. Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310. · DOI · Paper page
  3. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001; 61: 6185–6193.
  4. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J . Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61: 8–13.
  5. Moll UM, LaQuaglia M, Benard J, Riou G . Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92: 4407–4411. · DOI · Paper page
  6. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J . p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001; 158: 2067–2077. · doi:10.1016/s0002-9440(10)64678-0
  7. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G . Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 1996; 16: 1126–1137. · DOI · Paper page
  8. Nikolaev AY, Li M, Puskas N, Qin J, Gu W . Parc: a cytoplasmic anchor for p53. Cell 2003; 112: 29–40. · DOI · Paper page
  9. Zaika A, Marchenko N, Moll UM . Cytoplasmically ‘sequestered’ wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999; 274: 27474–27480. · DOI
  10. Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM . Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci USA 1996; 93: 15190–15194. · DOI
  11. Rorie CJ, Weissman BE . The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines. Cancer Res 2004; 64: 7288–7295. · DOI
  12. Wang X, Zalcenstein A, Oren M . Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differ 2003; 10: 468–476. · DOI
  13. Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM . MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol Pharmacol 2001; 59: 135–143. · DOI
  14. Wolff A, Technau A, Ihling C, Technau-Ihling K, Erber R, Bosch FX et al. Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 2001; 20: 1307–1317. · DOI
  15. Nakamura S, Roth JA, Mukhopadhyay T . Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000; 20: 9391–9398. · DOI · Paper page
  16. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT . Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000; 20: 8458–8467. · DOI · Paper page
  17. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH . C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001; 21: 8521–8532. · DOI · Paper page
  18. Boyd SD, Tsai KY, Jacks T . An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2000; 2: 563–568. · DOI · Paper page
  19. Geyer RK, Yu ZK, Maki CG . The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000; 2: 569–573. · DOI · Paper page
  20. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416: 648–653. · DOI · Paper page
  21. Isaacs JS, Hardman R, Carman TA, Barrett JC, Weissman BE . Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth Differ 1998; 9: 545–555.
  22. Appella E, Anderson CW . Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268: 2764–2772. · DOI · Paper page
  23. Moll UM, Marchenko N, Zhang XK . p53 and Nur77/TR3 – transcription factors that directly target mitochondria for cell death induction. Oncogene 2006; 25: 4725–4743. · DOI · Paper page
  24. Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006; 66: 2138–2145. · DOI
  25. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848. · DOI · Paper page
  26. Shirangi TR, Zaika A, Moll UM . Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 2002; 16: 420–422. · DOI
  27. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM . Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 94–102. · DOI · Paper page
  28. Gu J, Nie L, Wiederschain D, Yuan ZM . Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol Cell Biol 2001; 21: 8533–8546. · DOI
  29. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358–2365. · DOI
  30. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006; 66: 9646–9655. · DOI · Paper page
  31. Marchenko ND, Zaika A, Moll UM . Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000; 275: 16202–16212. · DOI · Paper page

Cited by

Metadata

Authors
Becker, K., Marchenko, N. D., Maurice, M., & Moll, U. M.
Venue
Cell Death & Differentiation
Published
2007-03-23
Volume
14
Issue
7
Pages
1350-1360
ISSN
  • 1350-9047
  • 1476-5403
Cited by
45
References
9
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.